GuidelineUrologie (Heidelberg, Germany)2026
[Update renal cell carcinoma : Guideline update on small renal masses].
Guideline in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small renal masses (kidney tumors < 4 cm) are benign in up to 30% of cases and often exhibit slow growth, yet they are still frequently primarily managed by surgery. A tumor biopsy should be performed before initiating active surveillance. As up to 8% of renal tumors could have a hereditary component, risk factors such as a diagnosis before the age of 47 years old, bilateral or multifocal lesions and syndrome-associated extrarenal manifestations, should be systematically assessed and clarified by a genetic evaluation. In patients with clear cell renal cell carcinoma and intermediate-high or high recurrence risk, as well as in metastatic with no evidence of disease (MINED) cases, adjuvant treatment with pembrolizumab can be recommended.
Indexed as
Identifiers
42726211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.